Pharmacological Modulation of Th17

Author(s): Juan B. De Sanctis, Jenny V. Garmendia, Dolores Moreno, Nancy Larocca, Michael Mijares, Camilo Di Giulio, Margarita Salazar-Bookaman, Gabriella Wojewodka, Danuta Radzioch

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery
Continued as Recent Advances in Inflammation & Allergy Drug Discovery

Volume 3 , Issue 2 , 2009


Recently, a third subset of Th17 cells has been described. This T helper subset induces the release of chemokines and growth factors and causes neutrophil accumulation in several mammalian organs. Pharmacological intervention blocking Th17 generation as well as IL-17 signaling might prove useful in a variety of diseases including asthma, chronic obstructive pulmonary disease, Crohns disease, cystic fibrosis, multiple sclerosis, psoriatic disease and rheumatoid arthritis. Here, we describe the patents that address a potential pharmacological use of promoting or targeting IL-17.

Keywords: IL-17, IL-17 receptors, Th-17, Th-1, Th-2, autoimmune diseases, allergic diseases, retinoids, retinoid orphan receptors, inflammation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [149 - 156]
Pages: 8
DOI: 10.2174/187221309788489814
Price: $65

Article Metrics

PDF: 10